We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-5.05%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
-$155M
Cap. Flow
-$860M
Cap. Flow %
-25.49%
Top 10 Hldgs %
37.46%
Holding
92
New
13
Increased
23
Reduced
14
Closed
19
Avg Time Held
3.9 quarters
Top 10 Avg Time Held
4.1 quarters
Top 20 Avg Time Held
3.4 quarters

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$85.8M
2
KROS icon
Keros Therapeutics
KROS
+$61.7M
3
LEGN icon
Legend Biotech
LEGN
+$59.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$49.3M
5
GERN icon
Geron
GERN
+$28M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$40.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39M
3
ARVN icon
Arvinas
ARVN
+$31.6M
4
APLS icon
Apellis Pharmaceuticals
APLS
+$30.9M
5
DXCM icon
DexCom
DXCM
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 66.36%
2 Miscellaneous 33.64%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NBIX icon
1
Neurocrine Biosciences
NBIX
$13.7B
$123M 3.65%
901,790
-15,884
-2% -$1.96M
2023 Q1
7 quarters
XENE icon
2
Xenon Pharmaceuticals
XENE
$3.25B
$114M 3.39%
2,913,964
+206,709
+8% +$8.55M
2022 Q4
8 quarters
LEGN icon
3
Legend Biotech
LEGN
$3.79B
$96.9M 2.87%
2,977,951
+1,436,400
+93% +$59.5M
2022 Q4
8 quarters
CGON icon
4
CG Oncology
CGON
$5.46B
$94.2M 2.79%
3,283,317
+112,442
+4% +$3.85M
2024 Q1
3 quarters
GH icon
5
Guardant Health
GH
$21.9B
$87M 2.58%
2,847,931
-494,193
-15% -$13.9M
2023 Q2
6 quarters
ALGN icon
6
Align Technology
ALGN
$10.1B
$78.2M 2.32%
375,179
+63,500
+20% +$14.2M
2022 Q4
8 quarters
APGE icon
7
DELISTED
Apogee Therapeutics
APGE
$69.8M 2.07%
1,540,362
-102,864
-6% -$5.25M
2023 Q3
5 quarters
KNSA icon
8
Kiniksa Pharmaceuticals
KNSA
$6.14B
$68.3M 2.02%
3,452,447
+557,934
+19% +$12.7M
2024 Q1
3 quarters
APLS icon
9
DELISTED
Apellis Pharmaceuticals
APLS
$67M 1.99%
2,098,866
-1,026,317
-33% -$30.9M
2024 Q2
2 quarters
IRTC icon
10
iRhythm Holdings
IRTC
$3.47B
$63.6M 1.89%
705,391
-77,166
-10% -$6.06M
2022 Q4
8 quarters
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.03B
$62.3M 1.85%
2,332,196
+373,886
+19% +$11.9M
2024 Q3
1 quarter
DAWN icon
12
DELISTED
Day One Biopharmaceuticals
DAWN
$61.8M 1.83%
4,873,853
– –
2022 Q4
8 quarters
SYRE icon
13
Spyre Therapeutics
SYRE
$7.33B
$60M 1.78%
2,578,404
+388,568
+18% +$11.4M
2023 Q4
4 quarters
VKTX icon
14
Viking Therapeutics
VKTX
$3.28B
$59.5M 1.77%
1,479,666
+322,689
+28% +$18.4M
2024 Q1
3 quarters
TMDX icon
15
Transmedics
TMDX
$2.62B
$57.5M 1.7%
+922,100
New +$85.8M
2024 Q4
0 quarters
INSP icon
16
Inspire Medical Systems
INSP
$1.97B
$54.4M 1.61%
293,410
+54,499
+23% +$10.6M
2023 Q3
5 quarters
ARGX icon
17
argenx
ARGX
$51.9B
$49.7M 1.47%
80,766
-15,958
-16% -$9.35M
2023 Q4
4 quarters
TMO icon
18
Thermo Fisher Scientific
TMO
$249B
$46.7M 1.38%
+89,754
New +$49.3M
2024 Q4
0 quarters
MRVI icon
19
Maravai LifeSciences
MRVI
$974M
$45.5M 1.35%
8,353,287
– –
2023 Q2
6 quarters
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.76B
$44.4M 1.32%
364,900
-5,500
-1% -$674K
2024 Q2
2 quarters
PEN icon
21
Penumbra
PEN
$12.6B
$43.7M 1.29%
183,828
-177,600
-49% -$40.4M
2022 Q4
8 quarters
GKOS icon
22
Glaukos
GKOS
$9.82B
$43.3M 1.28%
288,876
-22,740
-7% -$3.13M
2022 Q4
8 quarters
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
$43.2M 1.28%
4,105,726
+716,787
+21% +$8.7M
2024 Q1
3 quarters
RGEN icon
24
Repligen
RGEN
$11.4B
$40.9M 1.21%
283,823
-112,958
-28% -$16.2M
2023 Q2
6 quarters
FNA icon
25
DELISTED
Paragon 28, Inc.
FNA
$39.6M 1.17%
3,834,809
-300,300
-7% -$2.42M
2023 Q1
7 quarters
1
2 3 4

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q4 2024 Portfolio in Review

As of Q4 2024, Braidwell held 92 positions worth $3.37B, down 4.4% from $3.53B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $860M in Q4 2024, closing 19 positions and reducing 14 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Transmedics worth $57.5M.

  • Braidwell's largest Q4 2024 buy was Transmedics: 922,100 shares worth $57.5M.
  • Braidwell added most to Keros Therapeutics in Q4 2024, an estimated $61.7M increase.
  • Braidwell's biggest Q4 2024 reduction was Penumbra, cutting an estimated $40.4M.
  • Braidwell fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $39M.
  • Braidwell's ten largest holdings make up 37% of its $3.37B portfolio in Q4 2024.
  • Braidwell opened 13 new positions and closed 19 in Q4 2024.
  • Braidwell's portfolio value fell 4.4% quarter-over-quarter to $3.37B.

Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.